Tislelizumab, Docetaxel Seacross 20 mg/ml concentrado para solução para perfusão, N-803 (NAI) clinical trials

Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

This study looks at new treatments for advanced lung cancer that has become resistant to previous immune-boosting therapies. It compares a combination of N-803, tislelizumab, and docetaxel against docetaxel alone, aiming to see if the combination helps people live longer.